Ambrosia pollen transcriptome
Ontology highlight
ABSTRACT:
REPOSITORIES: ENA
Similar Datasets
Project description:Molecular and immunological characterization of ragweed (Ambrosia artemisiifolia L.) pollen after exposure the plants to elevated ozone over a whole growing season
| PRJEB1513 | ENA
Project description:Ambrosia artemisiifolia Transcriptome
| PRJNA313256 | ENA
Project description:The Ambrosia Project: Characterization of a cDNA library derived from Giant Ragweed pollen
| PRJNA642906 | ENA
Project description:Ambrosia artemisiifolia Transcriptome or Gene expression
| PRJNA335689 | ENA
Project description:Characterizing restriction enzyme-associated loci in historic ragweed (Ambrosia artemisiifolia) voucher specimens using custom-designed RNA probes
| PRJNA339123 | ENA
Project description:Illumina sequencing of the common ragweed chloroplast genome (Ambrosia artemisiifolia L.)
| PRJEB22657 | ENA
Project description:Ambrosia artemisiifolia chloroplast genome raw sequence reads
| PRJNA383307 | ENA
Project description:Creation of a reference transcriptome for the invasive annual, Ambrosia artemisiifolia.
| PRJNA274314 | ENA
Project description:Analysis of gene-expression profiles by microarrays can be very useful to characterize new potential candidate genes, key regulatory networks, and to define phenotypes or molecular signatures to improve the diagnosis or classification of the disease. We have used this approach in the study of one of the major causes of allergic diseases in Mediterranean countries, the olive pollen response, in order to find differential molecular markers among five clinical groups, Non-allergic, Asymptomatic, Allergic but not to olive pollen, Non-treated, olive pollen allergic patients and Olive pollen allergic patients (under specific-immunotherapy). The results of gene-expression by principal components analysis (PCA) clearly showed five clusters of samples that correlated with the five clinical groups. Analysis of differential gene-expression by multiple testing, and functional analysis by KEGG and Gene-Ontology revealed differential genes and pathways among the 5 clinical groups. The study population comprised 28 subjects, selected from a previous immunological study (Aguerri et al. Eur. J. Inflammation 2012, in press), from Andalusia, who were recruited in 2 olive pollen exposure situations: during (April-June) and outside the pollen season (October-December). We established 5 groups, and 6 subjects from each group were selected for gene-expression analysis: Group 1, non-allergic subjects; Group 2, asymptomatic subjects (diagnosed with olive pollen allergy by skin testing, with no seasonal respiratory symptoms [rhinitis and/or asthma], and who consulted for adverse reaction to drugs); Group 3, patients who were allergic, but not to olive pollen; Group 4, non-treated olive pollenM-bM-^@M-^Sallergic; and Group 5, olive pollenM-bM-^@M-^Sallergic patients (receiving olive pollenM-bM-^@M-^Sspecific immunotherapy).The subjects were unrelated and recruited at the Allergy Service of 4 hospitals in Andalusia (Granada, JaM-CM-)n, Sevilla, and MM-CM-!laga). Olive pollenM-bM-^@M-^Sallergic patients fulfilled the following criteria: seasonal rhinitis and/or asthma from April to June, a positive skin prick test result for O. europaea pollen extract (ALK AbellM-CM-3, Madrid, Spain), and no previous immunotherapy. Informed consent was obtained from each subject. Ethical approval for the study was obtained from the Ethical and Research Committee of the participating hospitals. PBMCs were isolated from heparin-containing peripheral blood samples taken during and outside pollen season, by gradient centrifugation on Lymphoprep (Comercial Rafer, Zaragoza, Spain) following the manufacturerM-bM-^@M-^Ys instructions.
2013-02-28 | E-GEOD-37157 | biostudies-arrayexpress